MX2017013133A - Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona. - Google Patents
Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona.Info
- Publication number
- MX2017013133A MX2017013133A MX2017013133A MX2017013133A MX2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- fmd
- rapamycin
- dexamethasone
- standard
- Prior art date
Links
- 235000021439 fasting mimicking diet Nutrition 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title 1
- 229960003957 dexamethasone Drugs 0.000 title 1
- 229940127208 glucose-lowering drug Drugs 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- 230000001235 sensitizing effect Effects 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 4
- 238000002512 chemotherapy Methods 0.000 abstract 3
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000003642 hunger Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
- 230000037351 starvation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148451P | 2015-04-16 | 2015-04-16 | |
| PCT/US2016/028055 WO2016168802A2 (en) | 2015-04-16 | 2016-04-18 | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013133A true MX2017013133A (es) | 2018-09-07 |
Family
ID=57126369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013133A MX2017013133A (es) | 2015-04-16 | 2016-04-18 | Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160303056A1 (enExample) |
| EP (2) | EP3283073A4 (enExample) |
| JP (2) | JP2018511625A (enExample) |
| KR (1) | KR20180002677A (enExample) |
| CN (1) | CN107613979A (enExample) |
| AU (1) | AU2016248443B2 (enExample) |
| BR (1) | BR112017022244A2 (enExample) |
| CA (2) | CA3108664A1 (enExample) |
| HK (1) | HK1249858A1 (enExample) |
| IL (1) | IL255026A0 (enExample) |
| MX (1) | MX2017013133A (enExample) |
| RU (1) | RU2734774C2 (enExample) |
| WO (1) | WO2016168802A2 (enExample) |
| ZA (1) | ZA201707710B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023748A2 (pt) | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
| RU2018131403A (ru) | 2016-02-15 | 2020-03-17 | Юниверсити Оф Саутерн Калифорния | Комбинации лекарственных средств и способы стимуляции эмбрионоподобной регенерации для лечения сахарного диабета и других заболеваний |
| AU2017261723B2 (en) | 2016-05-11 | 2023-02-09 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases. |
| WO2018102393A1 (en) * | 2016-11-30 | 2018-06-07 | Cure Cancer Worldwide Llc | System for chemotherapy delivery and method of the same |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| AU2019236242A1 (en) | 2018-03-15 | 2020-10-01 | University Of Southern California | Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology |
| CN113194752A (zh) | 2018-06-01 | 2021-07-30 | 康奈尔大学 | Pi3k相关疾病或病症的组合疗法 |
| WO2020191356A1 (en) * | 2019-03-21 | 2020-09-24 | Goncalves Marcus | Anti-fructose therapy for colorectal and small intestine cancers |
| JP2022530671A (ja) | 2019-04-30 | 2022-06-30 | ユニバーシティ オブ サザン カリフォルニア | アルツハイマー病（ａｄ）の介入のための断食模倣食（ｆｍｄ） |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| EP4164407A4 (en) * | 2020-06-14 | 2024-08-28 | L-Nutra Inc. | BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE |
| EP4180047A4 (de) * | 2020-07-10 | 2024-03-13 | Martynova, Elena Anatol'evna | Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2779282C (en) * | 2009-10-22 | 2017-12-05 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| CA2820384A1 (en) * | 2010-12-06 | 2012-06-14 | Cure Cancer Worldwide Corporation | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| US9237761B2 (en) * | 2013-02-12 | 2016-01-19 | University Of Southern California | Methods and diets for lowering glucose and/or IGF-1 levels |
| AU2014284399B2 (en) * | 2013-07-01 | 2017-10-26 | University Of Southern California | Fasting condition as dietary treatment of diabetes |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
-
2016
- 2016-04-18 CA CA3108664A patent/CA3108664A1/en not_active Abandoned
- 2016-04-18 RU RU2017136423A patent/RU2734774C2/ru active
- 2016-04-18 WO PCT/US2016/028055 patent/WO2016168802A2/en not_active Ceased
- 2016-04-18 JP JP2017553410A patent/JP2018511625A/ja active Pending
- 2016-04-18 HK HK18109338.2A patent/HK1249858A1/zh unknown
- 2016-04-18 KR KR1020177032463A patent/KR20180002677A/ko not_active Ceased
- 2016-04-18 BR BR112017022244A patent/BR112017022244A2/pt not_active IP Right Cessation
- 2016-04-18 CN CN201680022154.8A patent/CN107613979A/zh active Pending
- 2016-04-18 MX MX2017013133A patent/MX2017013133A/es unknown
- 2016-04-18 EP EP16780985.4A patent/EP3283073A4/en not_active Ceased
- 2016-04-18 US US15/131,586 patent/US20160303056A1/en not_active Abandoned
- 2016-04-18 CA CA2982875A patent/CA2982875C/en active Active
- 2016-04-18 EP EP23209796.4A patent/EP4299061A3/en active Pending
- 2016-04-18 AU AU2016248443A patent/AU2016248443B2/en active Active
-
2017
- 2017-10-15 IL IL255026A patent/IL255026A0/en unknown
- 2017-11-14 ZA ZA2017/07710A patent/ZA201707710B/en unknown
-
2020
- 2020-10-02 JP JP2020168000A patent/JP2021008491A/ja active Pending
-
2021
- 2021-01-12 US US17/147,280 patent/US20210137856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3283073A2 (en) | 2018-02-21 |
| RU2017136423A3 (enExample) | 2019-09-04 |
| CN107613979A (zh) | 2018-01-19 |
| ZA201707710B (en) | 2019-04-24 |
| HK1249858A1 (zh) | 2018-11-16 |
| CA3108664A1 (en) | 2016-10-20 |
| RU2017136423A (ru) | 2019-05-16 |
| EP4299061A2 (en) | 2024-01-03 |
| US20210137856A1 (en) | 2021-05-13 |
| AU2016248443A1 (en) | 2017-11-02 |
| RU2734774C2 (ru) | 2020-10-23 |
| KR20180002677A (ko) | 2018-01-08 |
| AU2016248443B2 (en) | 2021-03-18 |
| US20160303056A1 (en) | 2016-10-20 |
| CA2982875C (en) | 2021-10-19 |
| BR112017022244A2 (pt) | 2018-07-10 |
| IL255026A0 (en) | 2017-12-31 |
| EP3283073A4 (en) | 2019-02-13 |
| EP4299061A3 (en) | 2024-02-28 |
| WO2016168802A2 (en) | 2016-10-20 |
| JP2018511625A (ja) | 2018-04-26 |
| JP2021008491A (ja) | 2021-01-28 |
| CA2982875A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4299061A3 (en) | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone | |
| Kale et al. | Targeting ion channels for cancer therapy by repurposing the approved drugs | |
| Nagrial et al. | Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| PH12019502316A1 (en) | Combination cancer immunotheraphy with pentaaza macrocyclic ring complex | |
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| JP2018511625A5 (enExample) | ||
| Hill et al. | How cancer therapeutics cause accelerated aging: Insights from the hallmarks of aging | |
| BR112018007139A2 (pt) | ?método de proteção contra lesão de isquemia-reperfusão, e, método para tratar ou proteger um sujeito de afinamento ou perda da cfnr e lesão de isquemia-reperfusão associada a tratamento ivav? | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| MX2016016667A (es) | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| BR112017004292A2 (pt) | unidade de infusão, para a preparação sequencial de uma bebida, bem como dispositivo e processo para preparaçáo de uma bebida de pelo menos duas cápsulas | |
| NZ734252A (en) | Blockers of the growth hormone receptor in disease prevention and treatment | |
| Sivolap et al. | Wernicke encephalopathy and Korsakoff's psychosis: clinical-pathophysiological correlation, diagnostics and treatment | |
| IL283422A (en) | Methods of treating or preventing asthma by adding an IL-4R antagonist | |
| Jiang | Fotemustine/oxaliplatin | |
| UA99731U (ru) | Способ лечения мукополисахаридозов у больных разных возрастных групп | |
| Manmuan | EFFECTS OF SALINOMYCIN ON CELL VIABILITY, MIGRATION, INVASION AND INCREASING TAMOXIFEN SENSITIVITY IN ANTI-ESTROGEN RESISTANT BREAST CANCER CELLS | |
| UA90868U (uk) | Спосіб профілактики контраст-індукованої нефропатії | |
| Fujita | Mechanisms of resistance to molecular targeted drugs | |
| UA111014C2 (uk) | Спосіб лікування генералізованих тривожних розладів онкологічних хворих, які перенесли хірургічне втручання з формуванням кишкової стоми | |
| Arruti | Cyanocobalamin/dexamethasone/lidocaine/thiamine | |
| UA94513U (uk) | Спосіб лікування дисменореї в дівчат-підлітків |